Navigation Links
Affymetrix 500K array used to identify memory gene

Affymetrix Inc. announced today that researchers at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona have used the Affymetrix 500K Array to discover a gene--called Kibra--associated with memory performance in humans. The team's findings may be used to develop new medicines for memory-based diseases such as Alzheimer's and Parkinson's by providing scientists with a better understanding of how memory works at the molecular level.

The study entitled, "Common KIBRA alleles are associated with human memory performance," will be published in the Oct. 20, 2006 issue of Science. The research team was led by Dietrich Stephan, Ph.D., director of TGen's Neurogenomics Division. It included colleagues at the University of Zurich in Switzerland, Banner Alzheimer's Institute and Mayo Clinic Scottsdale.

"Using the latest Affymetrix 500K Array, we have shed light on the fundamental biological process of human memory performance," said Dr. Stephan. "We can use this new understanding to develop drugs that will improve memory function."

Until now, researchers did not have access to the high-density technology needed to examine the genetic components associated with memory performance. The team at TGen used Affymetrix Human Mapping 500K Arrays to analyze 500,000 DNA markers simultaneously, providing a genetic blueprint for the memory-study participants. The researchers discovered the Kibra gene by comparing the genetic blueprints of people with good memory vs. poor memory and looking for the genetic variations consistently present in one group, but not the other. They then validated their discovery by replicating the Kibra gene finding in two separate and distinct groups of subjects.

"This memory study is a perfect example of how the use of advanced technologies in human genetics yields fundamental discoveries," said Stephen P.A. Fodor, Ph.D., chairman and CEO at Affymetrix.

To learn more about this breakthrough:


'"/>

Source:Affymetrix, Inc.


Related biology news :

1. Affymetrix Unveils Plans to Double Plant and Animal Genome Microarray Offering
2. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
3. Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance
4. Affymetrix and Stratagene Announce Strategic Software Alliance
5. Affymetrix Licenses Microfluidics Technology From Caliper Life Sciences
6. Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX
7. Affymetrix and bioMerieux Extend Their Agreement on GeneChip(R) Technology to Breast Cancer Diagnostics
8. Affymetrix and ParAllele Launch Industrys Most Comprehensive Product Line for Targeted Genotyping
9. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status
10. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
11. Breakthrough Microarray-based Technology for the Study of Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/13/2017)... WASHINGTON , Feb. 13, 2017 Former ... U.S. Senate Judiciary Committee, Janice Kephart of ... regarding President Donald Trump,s "Executive Order: Protecting ... States" (Jan. 27, 2017):  "As President Trump,s ... 9th Circuit has now essentially banned the travel ban, ...
(Date:2/8/2017)...  Aware, Inc. (NASDAQ: AWRE ), a leading ... for its quarter and year ended December 31, 2016. ... $3.9 million compared to $6.9 million in the same quarter ... was $0.6 million compared to $2.6 million in the fourth ... 2016 was $0.5 million, or $0.02 per diluted share, which ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... , Feb. 24, 2017 Provectus Biopharmaceuticals, ... the "Company"), a clinical-stage oncology and dermatology biopharmaceutical ... deadline to participate in its previously announced rights ... of shares of common stock and Series C ... of listed warrants. As previously ...
(Date:2/24/2017)... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing and stem ... for the third quarter and first nine months of ... Third Quarter of Fiscal 2017 Highlights ... by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... Feb. 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ... host a Key Opinion Leader event to highlight new ... and poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology ... event will be held in-person and via live webcast ... 9:00 AM PST at the Lotte New York Palace ...
(Date:2/23/2017)... , Feb. 23, 2017 /PRNewswire/ - The Fight Against ... Cancer Research (OICR) are pleased to report that Fusion ... financing, with Johnson & Johnson Innovation – JJDC, Inc. ... venture groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, ... ...
Breaking Biology Technology: